Literature DB >> 30250873

Targeting the KEAP1/NRF2 pathway to manipulate the expression of oncogenic and oncosuppressive miRNAs in human leukemia.

Kristian M Bowles1,2, Stuart A Rushworth1.   

Abstract

The Kelch-like ECH-associated protein 1 (KEAP1)/nuclear factor E2-related factor 2 (NRF2L2, best known as NRF2) pathway plays a pivotal cytoprotective role in the regulation of cellular responses to oxidative stress. We report that NRF2 modulates the expression of microRNA-125B and microRNA-29B in acute myeloid leukemia. The regulation of microRNA in leukemia can now be added to the growing list of prosurvival functions of NRF2.

Entities:  

Year:  2018        PMID： 30250873      PMCID： PMC6149780          DOI： 10.4161/23723556.2014.988484

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway.

Authors:  John D Hayes; Michael McMahon; Sudhir Chowdhry; Albena T Dinkova-Kostova
Journal:  Antioxid Redox Signal       Date:  2010-08-14       Impact factor: 8.401

2.  TNF mediates the sustained activation of Nrf2 in human monocytes.

Authors:  Stuart A Rushworth; Suharsh Shah; David J MacEwan
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

3.  NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer.

Authors:  Tatsuhiro Shibata; Akiko Kokubu; Shigeru Saito; Mako Narisawa-Saito; Hiroki Sasaki; Kazuhiko Aoyagi; Yuki Yoshimatsu; Yuji Tachimori; Ryoji Kushima; Tohru Kiyono; Masayuki Yamamoto
Journal:  Neoplasia       Date:  2011-09       Impact factor: 5.715

4.  An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements.

Authors:  K Itoh; T Chiba; S Takahashi; T Ishii; K Igarashi; Y Katoh; T Oyake; N Hayashi; K Satoh; I Hatayama; M Yamamoto; Y Nabeshima
Journal:  Biochem Biophys Res Commun       Date:  1997-07-18       Impact factor: 3.575

5.  The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance.

Authors:  Stuart A Rushworth; Lyubov Zaitseva; Megan Y Murray; Niraj M Shah; Kristian M Bowles; David J MacEwan
Journal:  Blood       Date:  2012-10-17       Impact factor: 22.113

6.  Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis.

Authors:  Anju Singh; Christine Happel; Soumen K Manna; George Acquaah-Mensah; Julian Carrerero; Sarvesh Kumar; Poonam Nasipuri; Kristopher W Krausz; Nobunao Wakabayashi; Ruby Dewi; Laszlo G Boros; Frank J Gonzalez; Edward Gabrielson; Kwok K Wong; Geoffrey Girnun; Shyam Biswal
Journal:  J Clin Invest       Date:  2013-06-10       Impact factor: 14.808

7.  NRF2-driven miR-125B1 and miR-29B1 transcriptional regulation controls a novel anti-apoptotic miRNA regulatory network for AML survival.

Authors:  N M Shah; L Zaitseva; K M Bowles; D J MacEwan; S A Rushworth
Journal:  Cell Death Differ       Date:  2014-10-17       Impact factor: 15.828

8.  miR-125b transcriptionally increased by Nrf2 inhibits AhR repressor, which protects kidney from cisplatin-induced injury.

Authors:  M S Joo; C G Lee; J H Koo; S G Kim
Journal:  Cell Death Dis       Date:  2013-10-31       Impact factor: 8.469

9.  Identification of novel NRF2-regulated genes by ChIP-Seq: influence on retinoid X receptor alpha.

Authors:  Brian N Chorley; Michelle R Campbell; Xuting Wang; Mehmet Karaca; Deepa Sambandan; Fatu Bangura; Peng Xue; Jingbo Pi; Steven R Kleeberger; Douglas A Bell
Journal:  Nucleic Acids Res       Date:  2012-05-11       Impact factor: 16.971

10.  miRBase: annotating high confidence microRNAs using deep sequencing data.

Authors:  Ana Kozomara; Sam Griffiths-Jones
Journal:  Nucleic Acids Res       Date:  2013-11-25       Impact factor: 16.971
  10 in total
  1 in total

1.  The Role of MiRNA in Cancer: Pathogenesis, Diagnosis, and Treatment.

Authors:  Erez Uzuner; Gizem Tugçe Ulu; Sevim Beyza Gürler; Yusuf Baran
Journal:  Methods Mol Biol       Date:  2022
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.